Research Article| Volume 78, ISSUE 1, P17-28, March 1987

Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex

      This paper is only available as a PDF. To read, Please Download here.


      The terminal complement complex (TCC) was determined in plasma and cerebrospinal fluid (CSF) from 208 neurological patients. Elevated CSF TCC levels were observed in higher frequencies in patients with infectious diseases (80%), radiculoneuritis (62%), multiple sclerosis (30%), and miscellaneous autoimmune diseases (27%) than in patients with miscellaneous non-inflammatory diseases (2–13%). The plasma level of TCC was significantly increased only in the infectious group. No positive correlation was observed between the plasma and the CSF TCC concentration in the whole patient population nor in subgroups divided according to blood-brain barrier function. Furthermore, the CSF TCC concentration did not correlate with the serum/CSF albumin ratio or with CSF total protein concentration when this was below 1.0 g/l. It is concluded that an elevated TCC concentration in CSF reflects intrathecal complement activation and that quantification of TCC in CSF may be a valuable supplement in the examination of neurological diseases.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bhakdi S.
        • Tranum-Jensen J.
        Membrane damage by complement.
        Biochim. Biophys. Acta. 1983; 737: 343-372
        • Bradbury K.
        • Aparicio S.R.
        • Sumner D.W.
        • Bird C.C.
        Role of complement in demyelination in vitro by multiple sclerosis serum and other neurological disease sera.
        J. Neurol. Sci. 1984; 65: 293-305
        • Brown B.W.
        • Hollander M.
        Statistics — A Biomedical Introduction.
        in: John Wiley and Sons, Chichester1977: 292-340
        • Cyong J.C.
        • Witkin S.S.
        • Rieger B.
        • Barbarese E.
        • Good R.A.
        • Day N.K.
        Antibody-independent complement activation by myelin via the classical pathway.
        J. Exp. Med. 1982; 155: 587-598
        • Dube V.E.
        • McDuffie F.C.
        • Burton R.C.
        • Ilstrup D.
        Cerebrospinal fluid complement in multiple sclerosis.
        J. Lab. Clin. Med. 1973; 81: 530-537
        • Falk R.J.
        • Dalmasso A.P.
        • Kim Y.
        • Lam S.
        • Michael A.
        Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.
        N. Engl. J. Med. 1985; 312: 1594-1599
        • Goust J.M.
        • Chenais F.
        • Carnes J.E.
        • et al.
        Abnormal T-cell subpopulations and circulation immune complexes in the Guillain-Barré syndrome and multiple sclerosis.
        Neurology. 1978; 28: 421-425
        • Jans H.
        • Heltberg A.
        • Zeeberg I.
        • Kristensen J.Halkjær
        • Fog T.
        • Raun N.E.
        Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis.
        Acta Neurol. Scand. 1984; 69: 34-38
        • Kuwert E.
        • Pette E.
        • Firnhaber W.
        • Mai K.
        Demonstration of complement in spinal fluid in multiple sclerosis.
        Ann. N.Y. Acad. Sci. 1965; 122: 429-438
        • Lachmann P.J.
        Biology of the complement system: A summary.
        Progr. Immunol. 1983; 5: 445-452
        • Lachmann P.J.
        • Peters D.K.
        in: Lachmann P.J. Peters D.K. Clinical Aspects of Immunology. 4th edition. Blackwell Scientific Publications, Oxford1982: 18-49
        • Link H.
        Complement factors in multiple sclerosis.
        Acta Neurol. Scand. 1972; 48: 521-528
        • Liu W.T.
        • Vanguri P.
        • Shin M.L.
        Studies on demyelination in vitro: the requirement of membrane attack components of the complement system.
        J. Immunol. 1983; 131: 778-782
        • Mollnes T.E.
        Early - and late - phase activation of complement evaluated by plasma levels of C3dg and the terminal complement complex.
        Complement. 1985; 2: 156-164
        • Mollnes T.E.
        • Lea T.
        • Harboe M.
        Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay.
        Scand. J. Immunol. 1984; 20: 157-166
        • Mollnes T.E.
        • Fr∅land S.S.
        • Harboe M.
        Increased plasma levels of the terminal complement complex in patients with evidence of complement activation.
        Complement. 1985; 2: 175-184
        • Mollnes T.E.
        • Lea T.
        • Fr∅land S.S.
        • Harboe M.
        Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.
        Scand. J. Immunol. 1985; 22: 197-202
        • Mollnes T.E.
        • Lea T.
        • Harboe M.
        • Tschopp J.
        Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma.
        Scand. J. Immunol. 1985; 22: 183-195
        • Mollnes T.E.
        • Lea T.
        • Mellbye O.J.
        • Pahle J.
        • Grand Ø.
        • Harboe M.
        Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex.
        Arthr. Rheum. 1986; 29: 715-721
        • Morgan B.P.
        • Campbell A.K.
        • Compston D.A.S.
        Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis.
        Lancet. 1984; ii: 251-254
        • Müller-Eberhard H.J.
        The membrane attack complex.
        Springer Seminar Immunopath. 1984; 7: 93-141
        • Nikoskelainen E.
        • Irjala K.
        • Salmi T.T.
        Cerebrospinal fluid findings in patients with optic neuritis.
        Acta Ophthalmol. 1975; 53: 105-119
        • Price P.
        • Cuzner M.L.
        Cerebrospinal fluid complement proteins in neurological disease.
        J. Neurol. Sci. 1980; 46: 49-54
        • Ruddy S.
        Plasma protein effectors of inflammation: Complement.
        in: Kelly W.N. Harris E.D. Ruddy S. Sledge C.B. Textbook of Rheumatology. WB Saunders, Philadelphia1985: 83-94
        • Schuller E.
        • Allinquant B.
        • Garcia M.
        • Lefevre M.
        • Moreno P.
        • Tompe L.
        Électro-immunidiffusion des protéines de liquide céphalo-rachidien.
        Clin. Chim. Acta. 1971; 33: 5-11
        • Silverman B.A.
        • Carney D.F.
        • Johnston C.A.
        • Vanguri P.
        • Shin M.L.
        Isolation of membrane attack complex of complement from myelin membranes treated with serum complement.
        J. Neurochem. 1984; 42: 1024-1029
        • Tibbling G.
        • Link H.
        • Øhman S.
        Principles of albumin and IgG analyses in neurological disorders, Part 1 (Establishment of reference values).
        Scand. J. Clin. Lab. Invest. 1977; 37: 385-390
        • Trouillas P.
        • Aimard G.
        • Berthonx F.
        • Devic F.
        Multiple sclerosis with hypocomplementaemia.
        Lancet. 1975; ii: 932
        • Yam P.
        • Petz L.D.
        • Tourtellotte W.W.
        • Ma B.I.
        Measurement of complement components in cerebral spinal fluid by radioimmunoassay in patients with multiple sclerosis.
        Clin. Immunol. Immunopath. 1980; 17: 492-505